Background: Vancomycin is increasingly used by continuous infusion, but few specific data are available about stability under practical conditions of preparation and use, and compatibility with other intravenous drugs commonly used in the routine hospital setting.
Introduction
Vancomycin is increasingly used by continuous infusion because of facilitated monitoring (sampling time is not critical after the first loading dose, making interpretation of blood levels and pharmacokinetic calculations easier), potential decreased toxicity, easier nursing and the possibility of centralized preparation of ready-to-use solutions. 1 -4 To safely implement this mode of administration in a routine hospital setting it is, however, essential to ensure that vancomycin remains stable over the whole process and that incompatibilities with other medications co-administered by the intravenous route are avoided. Vancomycin has been repeatedly reported to be stable in various media for several days (see Nornoo and Elwell, 5 LaPlante et al. 6 and Dotson et al. 7 ), but few studies have been performed in the actual conditions of its clinical use, including potentially accidental exposure to high temperatures. Concerning compatibility, vancomycin is notorious for being incompatible with several b-lactams, 8 -10 but few studies have examined other antibiotics or other commonly used drugs that are administered by the intravenous route in routine clinical practice.
In preparation for the implementation of continuous infusion of vancomycin in all non-intensive care unit wards of a 400 bed hospital, we initiated a study in which: (i) the stability of the drug # The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com under the actual conditions of its use in patients (from its preparation in the Central Pharmacy to the end of the infusion) and after exposure to high temperatures was measured; and (ii) its compatibility with other drugs was tested in vitro using conditions mimicking their use in patients.
Materials and methods

Stability studies
These studies reproduced exactly the projected conditions of use of vancomycin by continuous infusion in our hospital. Hence, vancomycin (Vancocin w ; Lilly, Illkirch, France) solutions (10 g/L in 5% glucose) were prepared in 250 mL VIAFLO w polyolefin bags (coextruded layers of polyethylene, polyamide, polypropylene; Baxter s.a., Lessines, Belgium) and stored at 48C (for a maximum of 58 days; tested previously for stability 11 ) until transferred to the ward where they were maintained in a domestic refrigerator ( 48C) until about 15 min before use. Patients were infused at a rate of 11 mL/h if they had normal renal function (lower and higher rates were used in case of decreased or increased calculated CL CR ). The infusion was made with the bag exposed to uncontrolled room temperature and normal light for typically 24 h, but for up to 48 h for patients requiring low infusion rates. At the end of the infusion, the amount of fluid remaining in the bags was collected and assayed for vancomycin content. In parallel, samples of concentrated solution of vancomycin (up to 83 g/L) were incubated at increasing temperatures up to 508C and for up to 72 h to mimic situations that might cause an accelerated degradation such as: (i) the administration of vancomycin from motor-operated syringes (commonly used in several clinical set-ups and requiring the use of concentrated solutions); or (ii) accidental exposure to high temperatures during storage, transport and use.
Compatibility studies
For this study, drugs recommended for administration by the intravenous route were selected for: (i) their common association with vancomycin in clinical practice (antibiotics and antifungals); (ii) their common use in a hospital setting; and/or (iii) their known potential for incompatibility gained from an analysis of current databases. 12, 13 We used a protocol similar to that used by us for the study of the compatibility of b-lactam antibiotics with other drugs that mimic the conditions of their use when co-administered through the same line from two distinct containers via a Y connector. 14, 15 In brief, a solution of vancomycin at a concentration corresponding to its nominal concentration used in continuous infusion (10 g/L) was mixed with an equal volume of each of the tested drugs prepared at a concentration corresponding to its most common clinical use (taking into account the recommended concentration and time of infusion, as per the corresponding drug label; see Table 1 ). The mixtures were then kept at 378C for 1 h to mimic what could happen if the infusion flow was stopped for that period. The solutions, transferred to glass vials, were then examined with the naked eye for signs of physical incompatibility (e.g. precipitation, flocculation) or colour change using an Allen LV28 Liquid Viewer (PWAllen & Co. Ltd, Tewkesbury, UK) operated with two polarizing filters and compared with a pure solution of vancomycin and distilled water. Solutions were thereafter tested for the presence of non-visible particles by passing them through a particle analyser [Sub Micron Particle Analyser COULTER N 4 MD (Coulter Corp., Miami, FL, USA)] with a threshold set at twice the value of a pure solution of vancomycin. Chemical compatibility was assessed by determining the vancomycin content in comparison with an untreated sample.
Vancomycin assay and criteria for stability
We used a validated HPLC method with UV detection (diode array analysis for confirmation of the absorption spectrum) as described in detail in a previous publication 16 (but without the serum extraction procedure steps) and using pure, untreated vancomycin (vancomycin hydrochloride hydrate; Sigma-Aldrich, St Louis, MO, USA) as an external standard. Stability was defined as , 7% disappearance of the signal in a treated sample compared with an untreated control, in compliance with the provisions of the seventh Edition of the European Pharmacopoeia (online version) concerning the acceptable limit of content of vancomycin preparations (93%). 17 
Ethical approval
The protocol of this study (with respect to drug administration to patients) was approved by the Ethics Committee of the hospital in which the study was performed (CHU Mont-Godinne; internal number EC Mont-Godinne: 48/2007; unique Belgian number: B03920072246).
Results
The concentration of vancomycin in the remaining fluid of the infusion sets after up to 48 h was 10.1 g/L (n¼20; range: 9.6-10.3 g/L) compared with the initial nominal concentration of 10 g/L, thus complying with the provisions of the European Pharmacopoeia (.93%). Concentrated vancomycin solutions (up to 83 g/L) suffered ,5% degradation when kept for 72 h at up to 378C. Only samples exposed to 508C showed .7% degradation. Table 1 shows the results of the compatibility studies. For antiinfectives, four out of the five b-lactams with activity against Gram-negative bacteria tested (temocillin, piperacillin/tazobactam, ceftazidime, imipenem) were incompatible. Cefepime was physically and chemically compatible when mimicking its administration by continuous infusion (but its degradation was .10% after 24 h at 258C and after 14 h at 308C and ,10 h at 378C) and chemically incompatible when mimicking its thrice-daily administration. Flucloxacillin was also incompatible. Conversely, all three aminoglycosides tested (amikacin, tobramycin and gentamicin) were compatible. Among the fluoroquinolones, ciprofloxacin was compatible, but moxifloxacin was chemically incompatible. Macrolides (erythromycin and clarithromycin) and fluconazole were compatible.
For other drugs commonly used in hospitalized patients, sedatives (ketamine, sufentanil, midazolam, morphine and piritramide), antihypertensives (nicardipine and urapidil) and vasopressive drugs (dopamine, dobutamine and adrenaline) were all compatible. In contrast, propofol (mostly used as a hypnotic, but also for procedural sedation), valproic acid and phenytoin (anticonvulsants), theophylline (bronchodilator), methylprednisolone (glucocorticoid) and furosemide (diuretic) were all physically incompatible. In contrast to what had been observed with b-lactams, 14,15 N-acetyl-cysteine (used as an antioxidant in cases of paracetamol intoxication) did not cause alteration of vancomycin and nor did amino acid solutions (used for parenteral nutrition).
Discussion
This study is the first, to our knowledge, to systematically assess the stability and compatibility of vancomycin in conditions directly pertinent to its use by continuous infusion in hospitalized patients, with solutions kept at room temperature without replacement for up to 48 h and with attention paid to other drugs that could be co-administered through the same infusion Raverdy et al. Calculated (when appropriate) for a 70 kg male subject. c In final infusate. d Key: c, chemically and physically compatible; i, incompatible; phys, physically incompatible (precipitate, flocculation and/or presence of particles as evidenced by passing solutions through a particle analyser); chem, chemically incompatible-less than 93% recovery (. 7% loss of antibiotic compared with nominal content). e Physically and chemically compatible, but degradation of cefepime limits its stability to 24 h at 258C, 14 h at 308C and ,10 h at 378C (see Baririan et al. 15 ). line. The experimental set-up included conditions that could be accidentally encountered, such as exposure to high temperatures and prolonged contact of drugs in the infusion set in cases of flow arrest. While this may lead to overestimation of risk, it also heralds conditions that clinicians may need to carefully assess when dealing with specific situations and a patient's therapeutic needs. This is particularly important for incompatibilities with the anti-Gram-negative b-lactams (all classes). These antibiotics are indeed commonly associated with vancomycin in empirical therapies of severe infections. Incompatibility of vancomycin with ceftazidime, 18 cefpirome, 19 cefotaxime 9 and ceftriaxone 8 has already been described, but not studied in the context of continuous infusion of vancomycin. Although incompatibilities with b-lactams are often described as concentration dependent (as seen for cefepime here and reported for aztreonam 20 ), only very diluted solutions (down to 1 g/L) appear safe in this context, making these drugs quite difficult to use in practice. Thus, b-lactams should be considered as incompatible with vancomycin for all practical purposes, and their administration, if therapeutically needed, must imply specific measures such as the use of independent lines or multiple-way catheters, or the temporary suspension of the vancomycin infusion. Alternative anti-Gram-negative antibiotics such as aminoglycosides or ciprofloxacin may also offer a viable solution.
Globally speaking, the other incompatibilities detected are scattered among pharmacological classes without evidence of a specific relation to structure or biophysical properties. However, the number of drugs tested is limited. The main message is, therefore, that clinicians will need to request specific compatibility tests for all other drugs not mentioned here that they intend to use for specific patients. In this context, efforts coordinating various sources of information such as those appearing in monographs 13 or developed for online use (http ://www.stabilis.org) represent a useful development. It will, nevertheless, remain essential for practitioners to determine whether the conditions of testing actually apply to their projected use of the drug and, if not, to undertake the appropriate studies.
